Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Stocks Suffer Medicare Hangover; Aventis Bid Fails To Spark Rally

Executive Summary

Aventis is winning the battle to persuade investors that it is worth more than Sanofi says, but the budding bidding war for the company has not been enough to cure Wall Street's aversion to pharmaceutical stocks

You may also be interested in...



GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through

GlaxoSmithKline's conditional acquisition of Sanofi's antithrombotic brands would give GSK an almost free chance to build a potentially significant new product line in the U.S

GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through

GlaxoSmithKline's conditional acquisition of Sanofi's antithrombotic brands would give GSK an almost free chance to build a potentially significant new product line in the U.S

Aventis Pushes For Novartis Merger: Evokes European Pride In French Talks

Aventis believes a merger with Novartis would be more beneficial to Europe's pharmaceutical industry than a deal with Sanofi, the company said April 5

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel